NSCR activities led to the following results within the four overarching goals:
(i) We have created new tools to modify genes and viral delivery methods to develop improved cell types for future medical treatments. Our team has focused on enhancing the potential of stem cell-derived dopamine neurons for PD, refining their growth, transplantation, and interaction with their surroundings for better treatment outcomes. We also established a method to produce another type of brain cell, cholinergic neurons, which were successfully tested in animal models. New imaging technologies now allow us to study transplanted neurons in 3D, improving our understanding of how they develop and function. A cutting-edge sequencing method was introduced to precisely classify different dopamine neuron types. Additionally, we advanced techniques to directly reprogram brain cells, which could help restore key brain circuits in diseases like HD.
(ii) To develop novel strategies for cell-based repair, we have worked on improving how stem cell-derived neurons grow, function, and integrate into diseased brains. Our research explored how these cells interact with their environment and how targeted genetic tools can help control their activity. We also studied how the immune system responds to these cells to find ways to reduce rejection. By combining transplantation experiments, single-cell genetic analysis, and advanced viral vector screening tools, we gained valuable knowledge on maximizing the therapeutic benefits of these neurons and improving their long-term survival.
(iii) Our goal is to repair brain damage by replacing lost neurons and restoring neuronal circuits. We showed that transplanted human stem cells can develop into different types of brain cells like neurons and astrocytes. Depending on the combination of cell types in the transplant, they can form specific types of dopamine neurons. We also demonstrated that stem cells taken from blood can integrate into damaged brain tissue and form new synapses. Further studies confirmed that transplanted cortical neurons mature properly, and optogenetic tests showed they actively participate in brain functions, reinforcing their potential for treating brain injuries and diseases.
(iv) During this project, several new innovations were developed, leading to multiple patents and commercial products. Of the 15 innovations with commercial potential, some are still being developed, while others have already reached the market. These include a quality control tool for dopamine-producing cells and a new platform for advanced microscope imaging. Additionally, a newly identified marker for isolating dopamine-producing cells was sold to the industry, and a respective patent has been filed.
